Gilenya

DRUG5 trials

Sponsors

Massachusetts General Hospital, Jochen Vehoff, McGill University, University of Southern California, Genuine Research Center, Egypt

Conditions

Amyotrophic Lateral SclerosisAutonomic Nervous System DysfunctionHealthyMultiple SclerosisMultiple Sclerosis-Relapsing-Remitting

Phase 1

Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

CompletedNCT04657744

Genuine Research Center, EgyptHealthy

Start: 2020-08-10End: 2020-10-20Updated: 2020-12-08

Phase 2

Gilenya in Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT01786174

Massachusetts General HospitalAmyotrophic Lateral Sclerosis

Start: 2013-08-31End: 2015-05-31Updated: 2016-07-01

Phase 4

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

CompletedNCT02048072

Jochen VehoffAutonomic Nervous System Dysfunction, Multiple Sclerosis

Start: 2013-07-31End: 2015-06-30Updated: 2016-04-29

Unknown Phase

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

CompletedNCT02137707

McGill UniversityMultiple Sclerosis-Relapsing-Remitting

Start: 2012-11-30End: 2018-10-30Updated: 2018-11-09

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

CompletedNCT02225977

University of Southern CaliforniaMultiple Sclerosis

Start: 2013-07-31End: 2017-04-30Updated: 2018-08-22